Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy.

Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N.

Mod Pathol. 2019 Sep 2. doi: 10.1038/s41379-019-0358-x. [Epub ahead of print]

PMID:
31477811
2.

PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.

Bianchi A, Lopez S, Altwerger G, Bellone S, Bonazzoli E, Zammataro L, Manzano A, Manara P, Perrone E, Zeybek B, Han C, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Newberg JY, Pavlick DC, Elvin J, Frampton GM, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Aug 18. pii: S0090-8258(19)31461-1. doi: 10.1016/j.ygyno.2019.08.010. [Epub ahead of print]

PMID:
31434613
3.

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, González-Martín A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA.

Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135.

PMID:
31046082
4.

Prevalence and role of HER2 mutations in cancer.

Cocco E, Lopez S, Santin AD, Scaltriti M.

Pharmacol Ther. 2019 Jul;199:188-196. doi: 10.1016/j.pharmthera.2019.03.010. Epub 2019 Apr 2. Review.

PMID:
30951733
5.

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K.

N Engl J Med. 2019 Feb 21;380(8):741-751. doi: 10.1056/NEJMoa1814213.

PMID:
30786188
6.

Human Ovarian Cancer Tumor Formation in Severe Combined Immunodeficient (SCID) Pigs.

Boettcher AN, Kiupel M, Adur MK, Cocco E, Santin AD, Bellone S, Charley SE, Blanco-Fernandez B, Risinger JI, Ross JW, Tuggle CK, Shapiro EM.

Front Oncol. 2019 Jan 22;9:9. doi: 10.3389/fonc.2019.00009. eCollection 2019.

7.

PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.

Bonazzoli E, Cocco E, Lopez S, Bellone S, Zammataro L, Bianchi A, Manzano A, Yadav G, Manara P, Perrone E, Haines K, Espinal M, Dugan K, Menderes G, Altwerger G, Han C, Zeybek B, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2019 Apr;153(1):158-164. doi: 10.1016/j.ygyno.2019.01.002. Epub 2019 Jan 7.

PMID:
30630630
8.

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management.

Lopez S, Zeybek B, Santin AD.

Oncotarget. 2018 Nov 30;9(94):36652-36653. doi: 10.18632/oncotarget.26413. eCollection 2018 Nov 30. No abstract available.

9.

Ten-Year Comparison Study of Type 1 and 2 Endometrial Cancers: Risk Factors and Outcomes.

Feinberg J, Albright B, Black J, Lu L, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE.

Gynecol Obstet Invest. 2019;84(3):290-297. doi: 10.1159/000493132. Epub 2019 Jan 2.

PMID:
30602164
10.

Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors.

Li C, Bonazzoli E, Bellone S, Choi J, Dong W, Menderes G, Altwerger G, Han C, Manzano A, Bianchi A, Pettinella F, Manara P, Lopez S, Yadav G, Riccio F, Zammataro L, Zeybek B, Yang-Hartwich Y, Buza N, Hui P, Wong S, Ravaggi A, Bignotti E, Romani C, Todeschini P, Zanotti L, Zizioli V, Odicino F, Pecorelli S, Ardighieri L, Silasi DA, Litkouhi B, Ratner E, Azodi M, Huang GS, Schwartz PE, Lifton RP, Schlessinger J, Santin AD.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):619-624. doi: 10.1073/pnas.1814027116. Epub 2018 Dec 24. Erratum in: Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5829.

11.

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma.

Zeybek B, Lopez S, Santin AD.

Oncotarget. 2018 Oct 26;9(84):35470-35471. doi: 10.18632/oncotarget.26245. eCollection 2018 Oct 26. No abstract available.

12.

Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it.

Menderes G, Lopez S, Han C, Altwerger G, Gysler S, Varughese J, Schwartz PE, Santin AD.

Discov Med. 2018 Aug;26(141):39-50. Review.

13.

Novel targeted therapies in ovarian and uterine carcinosarcomas.

Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD.

Discov Med. 2018 Jun;25(140):309-319. Review.

14.

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report.

Han C, Bellone S, Schwartz PE, Govindan SV, Sharkey RM, Goldenberg DM, Santin AD.

Gynecol Oncol Rep. 2018 May 23;25:37-40. doi: 10.1016/j.gore.2018.05.009. eCollection 2018 Aug.

15.

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment.

Han C, Bellone S, Zammataro L, Schwartz PE, Santin AD.

Gynecol Oncol Rep. 2018 May 24;25:41-44. doi: 10.1016/j.gore.2018.05.011. eCollection 2018 Aug.

16.

Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.

Bonazzoli E, Predolini F, Cocco E, Bellone S, Altwerger G, Menderes G, Zammataro L, Bianchi A, Pettinella F, Riccio F, Han C, Yadav G, Lopez S, Manzano A, Manara P, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Schlessinger J, Santin AD.

Clin Cancer Res. 2018 Oct 1;24(19):4845-4853. doi: 10.1158/1078-0432.CCR-18-0864. Epub 2018 Jun 25.

PMID:
29941483
17.

Adjuvant Hormonal Therapy for Low-Grade Endometrial Stromal Sarcoma.

Deshmukh U, Black J, Perez-Irizarry J, Passarelli R, Levy K, Rostkowski A, Hui P, Rutherford TJ, Santin AD, Azodi M, Silasi DA, Ratner E, Litkouhi B, Schwartz PE.

Reprod Sci. 2019 May;26(5):600-608. doi: 10.1177/1933719118778801. Epub 2018 May 29.

PMID:
29843577
18.

Claudin3 is localized outside the tight junctions in human carcinomas.

Corsini M, Ravaggi A, Odicino F, Santin AD, Ravelli C, Presta M, Romani C, Mitola S.

Oncotarget. 2018 Apr 6;9(26):18446-18453. doi: 10.18632/oncotarget.24858. eCollection 2018 Apr 6.

19.

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.

Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O'Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD.

J Clin Oncol. 2018 Jul 10;36(20):2044-2051. doi: 10.1200/JCO.2017.76.5966. Epub 2018 Mar 27.

PMID:
29584549
20.

A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.

Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2018 Jun;149(3):585-591. doi: 10.1016/j.ygyno.2018.03.050. Epub 2018 Mar 21.

21.

MicroRNA signatures discriminate between uterine and ovarian serous carcinomas.

Hui P, Gysler SM, Uduman M, Togun TA, Prado DE, Brambs CE, Nallur S, Schwartz PE, Rutherford TJ, Santin AD, Weidhaas JB, Ratner ES.

Hum Pathol. 2018 Jun;76:133-140. doi: 10.1016/j.humpath.2018.02.019. Epub 2018 Mar 5.

PMID:
29518404
22.

In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.

Altwerger G, Bonazzoli E, Bellone S, Egawa-Takata T, Menderes G, Pettinella F, Bianchi A, Riccio F, Feinberg J, Zammataro L, Han C, Yadav G, Dugan K, Morneault A, Ponte JF, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Mol Cancer Ther. 2018 May;17(5):1003-1011. doi: 10.1158/1535-7163.MCT-17-0930. Epub 2018 Feb 13.

23.

Associated characteristics and impact on recurrence and survival of free-floating tumor fragments in the lumen of fallopian tubes in Type I and Type II endometrial cancer.

Albright BB, Black JD, Passarelli R, Gysler S, Whicker M, Altwerger G, Menderes G, Buza N, Hui P, Santin AD, Azodi M, Silasi DA, Ratner ES, Litkouhi B, Schwartz PE.

Gynecol Oncol Rep. 2018 Jan 9;23:28-33. doi: 10.1016/j.gore.2018.01.003. eCollection 2018 Feb.

24.

Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement.

Bellone S, Buza N, Choi J, Zammataro L, Gay L, Elvin J, Rimm DL, Liu Y, Ratner ES, Schwartz PE, Santin AD.

Clin Cancer Res. 2018 Jul 15;24(14):3282-3291. doi: 10.1158/1078-0432.CCR-17-1805. Epub 2018 Jan 19.

25.

Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.

Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black JD, Dugan K, Pettinella F, Masserdotti A, Riccio F, Bianchi A, Zammataro L, de Haydu C, Buza N, Hui P, Wong S, Huang GS, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Oct;147(1):145-152. doi: 10.1016/j.ygyno.2017.07.009. Epub 2017 Jul 10.

26.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.

Menderes G, Bonazzoli E, Bellone S, Black J, Predolini F, Pettinella F, Masserdotti A, Zammataro L, Altwerger G, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Clin Cancer Res. 2017 Oct 1;23(19):5836-5845. doi: 10.1158/1078-0432.CCR-16-2862. Epub 2017 Jul 5.

27.

Genetic landscape of clear cell endometrial cancer and the era of precision medicine.

Huang GS, Santin AD.

Cancer. 2017 Sep 1;123(17):3216-3218. doi: 10.1002/cncr.30743. Epub 2017 May 9. No abstract available.

28.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

29.

SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.

Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jul;146(1):179-186. doi: 10.1016/j.ygyno.2017.04.023. Epub 2017 May 1.

30.

Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo.

Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Med Oncol. 2017 May;34(5):91. doi: 10.1007/s12032-017-0956-8. Epub 2017 Apr 10.

31.

Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.

Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL.

Gynecol Oncol. 2017 Apr;145(1):154-158. doi: 10.1016/j.ygyno.2017.02.002. Epub 2017 Feb 11.

32.

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1).

Santin AD, Bellone S, Buza N, Schwartz PE.

Gynecol Oncol Rep. 2016 Dec 14;19:10-12. doi: 10.1016/j.gore.2016.12.003. eCollection 2017 Feb.

33.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells.

Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD.

Mol Cancer Ther. 2017 Feb;16(2):323-333. doi: 10.1158/1535-7163.MCT-16-0501. Epub 2016 Dec 12.

34.

Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade.

Roque DM, Santin AD.

Expert Rev Clin Immunol. 2017 Mar;13(3):175-180. doi: 10.1080/1744666X.2017.1266938. Epub 2016 Dec 12. No abstract available.

35.

Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.

Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD.

Gynecol Oncol. 2017 Jan;144(1):146-152. doi: 10.1016/j.ygyno.2016.11.023. Epub 2016 Nov 26.

36.

Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer.

Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W.

J Clin Invest. 2016 Nov 1;126(11):4157-4173. doi: 10.1172/JCI87252. Epub 2016 Oct 10.

37.

Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition.

Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):12238-12243. Epub 2016 Oct 10.

38.

The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines.

Bandiera E, Todeschini P, Romani C, Zanotti L, Erba E, Colmegna B, Bignotti E, Santin AD, Sartori E, Odicino FE, Pecorelli S, Tassi RA, Ravaggi A.

Oncol Lett. 2016 Oct;12(4):2493-2500. Epub 2016 Aug 16.

39.

Improved i.p. drug delivery with bioadhesive nanoparticles.

Deng Y, Yang F, Cocco E, Song E, Zhang J, Cui J, Mohideen M, Bellone S, Santin AD, Saltzman WM.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11453-11458. Epub 2016 Sep 23.

40.

Improved specific loss power on cancer cells by hyperthermia and MRI contrast of hydrophilic Fex Co1-x Fe2 O4 nanoensembles.

Hoque SM, Huang Y, Cocco E, Maritim S, Santin AD, Shapiro EM, Coman D, Hyder F.

Contrast Media Mol Imaging. 2016 Nov;11(6):514-526. doi: 10.1002/cmmi.1713. Epub 2016 Sep 22.

PMID:
27659164
41.

Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab.

Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, Lifton RP.

Clin Cancer Res. 2016 Dec 1;22(23):5682-5687. Epub 2016 Aug 2.

42.

Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.

Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD.

Br J Cancer. 2016 Jul 26;115(3):303-11. doi: 10.1038/bjc.2016.198. Epub 2016 Jun 28.

43.

SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.

Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD.

Mol Cancer Ther. 2016 Aug;15(8):1900-9. doi: 10.1158/1535-7163.MCT-16-0163. Epub 2016 Jun 2.

44.

Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.

Menderes G, Clark M, Santin AD.

Discov Med. 2016 Apr;21(116):293-303. Review.

45.

Oncofertility in gynecologic oncology: an oxymoron?

Roque DM, Santin AD.

Future Oncol. 2016 Jul;12(14):1683-6. doi: 10.2217/fon-2016-0167. Epub 2016 May 13. No abstract available.

PMID:
27173792
46.

Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.

Abu-Khalaf MM, Raza MA, Hatzis C, Wang H, Lin K, Higgins S, Ratner E, Silasi DA, Azodi M, Rutherford TJ, Santin AD, Schwartz PE.

Eur J Gynaecol Oncol. 2016;37(2):199-203.

PMID:
27172745
47.

Molecular diagnosis and molecular profiling to detect treatment-resistant ovarian cancer.

English DP, Menderes G, Black J, Schwab CL, Santin AD.

Expert Rev Mol Diagn. 2016 Jul;16(7):769-82. doi: 10.1080/14737159.2016.1188692. Epub 2016 May 27. Review. Erratum in: Expert Rev Mol Diagn. 2016 Oct;16(10 ):1133.

PMID:
27169329
48.

Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.

Menderes G, Hicks C, Black JD, Schwab CL, Santin AD.

Expert Opin Biol Ther. 2016 Aug;16(8):989-1004. doi: 10.1080/14712598.2016.1177018. Epub 2016 Apr 25. Review.

PMID:
27070175
49.

The Role of the Immune System in Ovarian Cancer and Implications on Therapy.

Menderes G, Schwab CL, Black J, Santin AD.

Expert Rev Clin Immunol. 2016 Jun;12(6):681-95. doi: 10.1586/1744666X.2016.1147957. Epub 2016 Feb 15. Review.

PMID:
26821930
50.

An update on the current pharmacotherapy for endometrial cancer.

de Haydu C, Black JD, Schwab CL, English DP, Santin AD.

Expert Opin Pharmacother. 2016;17(4):489-99. doi: 10.1517/14656566.2016.1127351. Epub 2015 Dec 23. Review.

PMID:
26629895

Supplemental Content

Loading ...
Support Center